Vortioxetine (trade name Brintellix and Trintellix in Canada) is an atypical antidepressant (a serotonin modulator and stimulator) made by Lundbeck and Takeda. On September 30, 2013, it was approved by the U.S. FDA for the treatment of major depressive disorder (MDD) in adults. Vortioxetine was also investigated as a treatment for generalized anxiety disorder (GAD) but was not found to be superior to placebo.
Following a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in October 2013, Lundbeck announced December 27, 2013, that European marketing authorization for Brintellix had been obtained. More: en.wikipedia.org.